.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Harvard Business School
Cerilliant
QuintilesIMS
Chubb
Medtronic
Chinese Patent Office
Fuji
McKinsey
Fish and Richardson

Generated: July 22, 2017

DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has eighty-eight approved drugs.

There are eighty-six US patents protecting ABBVIE drugs.

There are one thousand four hundred and twenty-four patent family members on ABBVIE drugs in sixty-nine countries.

Summary for Applicant: Abbvie

Patents:86
Tradenames:77
Ingredients:64
NDAs:88
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
HARMONYL
deserpidine
TABLET;ORAL010796-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000AARXYesYes6,911,214*PED► SubscribeY► Subscribe
Abbvie Inc
DUOPA
carbidopa; levodopa
SUSPENSION;ENTERAL203952-001Jan 9, 2015RXYesYes► Subscribe► Subscribe
Abbvie Endocrine Inc
LUPRON DEPOT-PED
leuprolide acetate
INJECTABLE;INJECTION020263-006Jan 21, 1994RXYesYes6,036,976► Subscribe ► Subscribe
Abbvie
ANDROGEL
testosterone
GEL;TRANSDERMAL021015-001Feb 28, 2000AB1RXYesNo9,125,816*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine Inc
LUPRON DEPOT
leuprolide acetate
INJECTABLE;INJECTION019732-001Jan 26, 19895,631,020► Subscribe
Abbvie
DEPAKOTE ER
divalproex sodium
TABLET, EXTENDED RELEASE;ORAL021168-001Aug 4, 20004,913,906*PED► Subscribe
Abbvie
KALETRA
lopinavir; ritonavir
CAPSULE;ORAL021226-001Sep 15, 20005,948,436*PED► Subscribe
Abbvie
VICOPROFEN
hydrocodone bitartrate; ibuprofen
TABLET;ORAL020716-001Sep 23, 19976,348,216► Subscribe
Abbvie
NUROMAX
doxacurium chloride
INJECTABLE;INJECTION019946-001Mar 7, 19914,701,460► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABBVIE drugs

Drugname Dosage Strength Tradename Submissiondate
lopinavir and ritonavir
Oral Solution80 mg/20 mg per mL
KALETRA
6/19/2014
testosterone
Gel1.62% (1.25 g and 2.5 g packets)
ANDROGEL
6/19/2013
ritonavir
Capsules100 mg
NORVIR
10/31/2012
testosterone
Gel1.62%
ANDROGEL
4/6/2012
ritonavir
Tablets100 mg
NORVIR
12/21/2010
clarithromycin
Extended-release Tablet500 mg
BIAXIN XL
12/6/2010
eprosartan mesylate
Tablets400 mg and 600 mg
TEVETEN
5/10/2010
fenofibrate choline
Delayed-release Capsules45 mg
TRILIPIX
9/2/2009
fenofibrate choline
Delayed-release Capsules135 mg
TRILIPIX
9/1/2009
cisatracurium besylate (multi-dose)
     Injection2 mg/mL, 10 mL vial
NIMBEX
8/12/2009
cisatracurium besylate (preserve free)
Injection2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial
NIMBEX
8/4/2009
lopinavir and ritonavir
Tablets100 mg/25 mg
KALETRA
12/23/2008
testosterone
Gel Metered-dose Pump1%
ANDROGEL
12/19/2008
paricalcitol
Injection0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials
ZEMPLAR
11/28/2008
paricalcitol
Capsules1 mcg and 2 mcg
ZEMPLAR
10/14/2008
paricalcitol
Capsules4 mcg
ZEMPLAR
8/25/2008
fenofibrate
Tablets48 mg
TRICOR
7/1/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets1 mg/240 mg
TARKA
2/20/2008
trandolapril and verapamil hydrochloride
Extended-release Tablets2 mg/180 mg and 2 mg/240 mg
TARKA
11/9/2007
fenofibrate
Tablets145 mg
TRICOR
10/19/2007
trandolapril and verapamil hydrochloride
Extended-release Tablets4 mg/ 240 mg
TARKA
7/24/2007
hydrocodone bitartrate and ibuprofen
Tablets2.5 mg/200 mg
VICOPROFEN
2/24/2006
hydrocodone bitartrate and ibuprofen
Tablets5 mg/200 mg
VICOPROFEN
5/27/2005
divalproex sodium
Extended-release Tablets500 mg
DEPAKOTE ER
2/8/2005
trandolapril
Tablets1 mg, 2 mg and 4 mg
MAVIK
10/4/2004
divalproex sodium
Extended-release Tablets250 mg
DEPAKOTE ER
5/3/2004

Non-Orange Book Patents for Abbvie

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,011,848Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor► Subscribe
7,850,995Bioadhesive nanoparticulate compositions having cationic surface stabilizers► Subscribe
6,313,296 Retroviral protease inhibiting compounds► Subscribe
8,323,641Nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
7,198,795In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Drugs

Country Document Number Estimated Expiration
Poland366117► Subscribe
Israel156236► Subscribe
South Korea20050026705► Subscribe
European Patent Office1217993► Subscribe
Georgia, Republic ofP20105083► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C/GB00/010United Kingdom► SubscribePRODUCT NAME: EPROSARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING EPROSARTAN MESYLATE; REGISTERED: DE 39 573.00.00 19970417; DE 39 573.01.00 19970417; DE 39 573.02.00 19970417; UK PL00512/0162 19990823; UK PL00512/0163 19990823; UK PL00512/0164 19990823
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
2368890/01Switzerland► SubscribePRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
US Department of Justice
US Army
Cerilliant
Healthtrust
Deloitte
Fuji
Merck
Fish and Richardson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot